期刊
TRENDS IN CANCER
卷 5, 期 5, 页码 283-296出版社
CELL PRESS
DOI: 10.1016/j.trecan.2019.02.010
关键词
-
类别
资金
- NIH [R01CA187090]
- Cancer Center Support Grant [CA051008]
- DF/HCC Kidney Cancer SPORE [CA101942]
- V foundation
- Toulmin Pilot Award
- Sher Grant
- Advocure foundation
Drug resistance is a major challenge in cancer treatment. Emerging evidence indicates that deregulation of YAP/TAZ signaling may be a major mechanism of intrinsic and acquired resistance to various targeted and chemotherapies. Moreover, YAP/TAZ-mediated expression of PD-L1 and multiple cytokines is pivotal for tumor immune evasion. While direct inhibitors of YAP/TAZ are still under development, FDA-approved drugs that indirectly block YAP/TAZ activation or critical downstream targets of YAP/TAZ have shown promise in the clinic in reducing therapy resistance. Finally, BET inhibitors, which reportedly block YAP/TAZ-mediated transcription, present another potential venue to overcome YAP/TAZ-induced drug resistance.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据